AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00770042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole
Description: Ketoconazole 400 mg qd for 5 days (Days 2-6)
Study NCT00770042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythomycin
Description: Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
Study NCT00770042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: Avanafil 50 mg on Days 1 and 8
Study NCT00770042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: Avanafil 50 mg on Days 1 and 6
Study NCT00770042 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avanafil
Description: Avanafil 200mg Days 1 and 6
Study NCT02789670 — intervention group
Intervention type: OTHER
Intervention: Blood sample collection
Description: Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
Study NCT04397913 — intervention group
Intervention type: DRUG
Intervention: Paracetamol
Description: 15 mg/kg, q6h
Study NCT04397913 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen
Description: 10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day
Study NCT00902018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: The 10 subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times, weekly, for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
Study NCT00902018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: three of the patients treated with eltrombopag will be treated with weekly romiplostim at a dose of 10 micrograms/kg weekly for 2 weeks with testing at weekly intervals for 3 times
Study NCT00902018 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: healthy controls
Description: single blood draw for all measures included in the intervention arms
Study NCT04579302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serratus anterior block (SAB)
Description: Patients will receive a sonar guided serratus anterior plane block with 20 ml of bupivacaine 0.5%
Study NCT04579302 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector spinae block
Description: Patients will receive a sonar-guided erector spinae plane block with 20 ml of bupivacaine 0.5%
Study NCT04579302 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Saline (as a placebo)
Description: Patients will receive a sham block with 20 ml saline (as a placebo)
Study NCT04579302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: bupivacaine
Study NCT04686760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Description: 2 mg/ml solution of nitroglycerin used for nebulization four hourly
Study NCT01529580 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Verbal School Aged Children with Autism (NVSACA) Intervention
Description: The intervention has 3 components:~1. One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.~2. Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.~3. Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training.
Study NCT00686322 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)
Description: Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
Study NCT00101816 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
Study NCT03826836 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction
Description: Mindfulness-based stress reduction (MBSR) is a structured programme of 8 weekly sessions of 2-2,5 hours in groups of 8-16 participants organized at the hospital sites. Additionally, participants are encouraged to practice each day for 30-45 minutes using audio-recordings of the guided exercises. The programme is provided by experienced mindfulness teachers according to the standard MBSR protocol, except for the all-day session.
Study NCT01413620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dl-alpha-tocopheryl acetate
Description: Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
Study NCT01119833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GMI-1070
Description: Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
Study NCT01119833 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
Study NCT03865667 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® Preserve Femoral Stem
Description: Total Hip Total Hip Arthroscopy
Study NCT03409406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ST Intervention
Description: This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
Study NCT04679857 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TKA
Description: Total Knee Arthroplasty
Study NCT03409406 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ST Intervention
Description: This intervention is the 30 minute speech and language therapy session provided to the child at the hospital once a month for three months.
Study NCT03131050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Scopolamine
Description: Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
Study NCT03131050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
Study NCT03131050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
Study NCT03131050 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
Study NCT03131050 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
Study NCT03736317 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham TBS
Description: Stimulate the dorsal lateral prefrontal cortex or medial prefrontal cortex for 2 weeks by sham Theta-burst stimulation (TBS), five times for a week with the sham coil.
Study NCT03736317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real mPFC cTBS
Description: Stimulate the medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
Study NCT03736317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real dlPFC iTBS
Description: Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
Study NCT03736317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: real dlPFC iTBS + real mPFC cTBS
Description: Stimulate the dorsal lateral prefrontal cortex with the iTBS pattern, and stimulate medial prefrontal cortex with the cTBS pattern. The therapy will be conducted for 2 weeks and five times for a week.
Study NCT02854735 — intervention group
Intervention type: OTHER
Intervention: Imaging by CT and densitometry
Description: Imaging by CT and densitometry, no intervention involved
Study NCT01580189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein
Description: 18g protein, immediately after training, 9 weeks
Study NCT01580189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Chocolate milk
Description: 500ml chocolate milk, immediately after training, 9 weeks
Study NCT04679857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TKA
Description: Total Knee Arthroplasty
Study NCT02252185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Johnson&Johnson Medical Suzhou made Spine Fusion System
Description: interventional device is Spine Fusion System that is manufactured by Johnson \& Johnson Medical Suzhou Ltd.
Study NCT02252185 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Imported EXPEDIUM screws and OPAL cage
Description: Comparator in this study is active comparator.
Study NCT02825966 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AUDICOR then LifeVest then AUDICOR
Description: Wearable Cardioverter Defibrillator to record acoustic cardiograph signals.
Study NCT02274272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ADR-1
Description: two ADR-1 capsules, once daily, QD
Study NCT02274272 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GMNL-263
Description: two GMNL-263 capsules, once daily, QD
Study NCT02274272 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two placebo capsules, once daily, QD
Study NCT03054805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Oxide
Description: Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight > 30 kg
Study NCT03054805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Oxide
Description: Magnesium oxide 250 mg per day for children with weight \< 15 kg, 500 mg per day for weight \<15-30 kg, and 1000 mg per day for weight > 30 kg
Study NCT03054805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MIYAIRI-BM
Description: MIYAIRI-BM 1 g (1package) per day for children with weight \< 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
Study NCT00832130 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Mini System
Description: In-office device treatment for meibomian gland dysfunction by a physician
Study NCT00832130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Mini System
Description: In-office device treatment for meibomian gland dysfunction by a physician
Study NCT00832130 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iHeat Portable Warm Compress Therapy
Description: At-home daily warm compress therapy
Study NCT02460783 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Boost (R) 5-2 diet
Description: Regular diet for 5 days/week; Calorie Restriction (480 Kcal in the form of a shake) for 2 days/week. Supplement providing 240 Kcal per shake. Participant takes 2 shakes per calorie restriction day.
Study NCT02460783 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Living Diet
Description: Counseling and educational material on diet portion, consistency
Study NCT03620552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-S16
Description: A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans
Study NCT00712530 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DermaVir
Description: DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
Study NCT00712530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAART
Description: Three or more antiretroviral drugs that can fully suppress HIV RNA
Study NCT02921555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
Study NCT02921555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
Study NCT02921555 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
Study NCT00002849 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant interferon alfa
Description: first 2 years
Study NCT00002849 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: 40 mg\*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles\*
Study NCT02094742 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: biopsy
Study NCT02781025 — intervention group
Intervention type: OTHER
Intervention: Blood draw
Description: A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
Study NCT03756363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-solvent
Description: Root canal filling removal using ProTaper retreatment instruments. Single session retreatment procedures.
Study NCT03756363 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Solvent
Description: Root canal filling removal using ProTaper retreatment instruments in combination with a gutta percha solvent. Single session retreatment procedures.
Study NCT03243214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS
Description: Real or Sham TMS will be given to the PD-MCI patient
Study NCT03243214 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-TMS
Description: Real or Sham TMS will be given to the PD-MCI patient
Study NCT03029195 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasoalveolar molding therapy
Description: Presurgical infant orthopedics
Study NCT00681694 — intervention group
Intervention type: RADIATION
Intervention: brachytherapy
Description: An experimental arm using MRI imaging and excluding the transition zone from the target volume
Study NCT00681694 — intervention group
Intervention type: RADIATION
Intervention: brachytherapy
Description: Standard ultrasound-guided brachytherapy with standard target volumes
Study NCT01543672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 3-5 fractions within 10-14 days
Study NCT01543672 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiotherapy (SBRT)
Description: 3-5 fractions per tumor within one treatment session or sequential within one month
Study NCT01228604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate (Ritalin®)
Description: The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
Study NCT02073838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Study NCT02073838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Study NCT02073838 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study NCT02076360 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preoperative Video
Description: Patients will watch preoperative instructional video
Study NCT01780714 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cigarettes (CC)
Description: Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
Study NCT01780714 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THS 2.1
Description: Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
Study NCT02299570 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RBX2660 (microbiota suspension)
Description: A suspension of intestinal microbes
Study NCT01580189 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sugar
Description: 55-65g maltodextrin solution, immediately after training, 9 weeks
Study NCT02031926 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Positive expiratory pressure
Study NCT03963362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 75 mg
Description: GLARS-NF3 tablet
Study NCT03963362 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA5PR tablet 150 mg
Description: GLARS-NF3 tablet
Study NCT03569540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide
Description: Placebo-controlled; Double blind test
Study NCT03569540 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Amylum
Study NCT03439020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plastic stent anchoring
Description: Insert an additional plastic stent to anchor the fully covered self expandable metal stent.
Study NCT03439020 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FCSEMS
Description: Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
Study NCT03439020 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FCSEMS
Description: Insert a fully covered self expandable metal stent (FCSEMS) for malignant biliary stricture
Study NCT01120912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oshadi Oral Insulin
Description: Oral insulin single administration
Study NCT03344432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: with intraocular pressure high
Description: Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
Study NCT02299570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A suspension of saline and cryoprotectant
Study NCT03344432 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: without intraocular pressure high
Description: Measurement of intraocular pressure The measurement will be made with a electronic minimum contact tonometer for measuring intraocular pressure immediately before the placement of the invasive catheter for measurement of intracranial pressure.
Study NCT02977689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDH305
Description: study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
Study NCT02299570 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: A suspension of saline and cryoprotectant
Study NCT02120092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: 1x Loading dose 600 mg 6x maintenance dose 150 mg
Study NCT02120092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 1x Loading dose 600 mg 6x maintenance dose 150 mg
Study NCT02120092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
Study NCT02120092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ticagrelor
Description: 1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
Study NCT02120092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: 7x 100mg acetylsalicylic acid (clopidogrel arm)~1x 300 mg acetylsalicylic acid (ticagrelor arm)
Study NCT02120092 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7x 300mg acetylsalicylic acid placebo
Study NCT04015037 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: placebo or drug
Description: Group A and B (medicated or placebo)